Parabolic Drugs

“The investigation of Parabolic Drugs and its directors has nothing to do with Ashoka," says university. CBI has filed a case against them and a few others of Parabolic Drugs for allegedly defrauding Central Bank of India and other banks of Rs 1,627 crore.

BSE resets circuit limit of Max India, 6 others

Circuit filter mechanism is used by stock exchanges to keep excessive volatility in check. It is the maximum fluctuation that is allowed during trading, which gets suspended if the permissible limit is hit in either direction.

BSE tweaks circuit limit of Tata Metaliks, 7 others

The new limits, which ensure that stock prices do not move up or down beyond a level during a trading session, will be effective from July 25.

Parabolic Drugs standalone Dec '13 sales at Rs 114.42 crore

Parabolic Drugs has reported a standalone sales turnover of Rs 114.42 crore and a net loss of Rs 24.46 crore for the quarter ended Dec '13

Parabolic Drugs standalone Sep '13 sales at Rs 117.12 crore

Parabolic Drugs has reported a standalone sales turnover of Rs 117.12 crore and a net loss of Rs 22.32 crore for the quarter ended Sep '13

Parabolic Drugs standalone Jun '13 sales at Rs 99.48 crore

Parabolic Drugs has reported a standalone sales turnover of Rs 99.48 crore and a net loss of Rs 23.95 crore for the quarter ended Jun '13

Parabolic Drugs standalone Dec '12 sales at Rs 152.24 crore

Parabolic Drugs has reported a standalone sales turnover of Rs 152.24 crore and a net loss of Rs 25.59 crore for the quarter ended Dec '12

Parabolic Drugs Sep '12 sales at Rs 251.65 crore

Parabolic Drugs has reported a sales turnover of Rs 251.65 crore and a net loss of Rs 25.25 crore for the quarter ended Sep '12

Parabolic Drugs Dec '11 sales at Rs 273.57 crore

Parabolic Drugs has reported a sales turnover of Rs 273.57 crore and a net profit of Rs 12.82 crore for the quarter ended Dec '11

Eyeing Rs 150cr from dosage biz in 3-5 yrs: Parabolic Drugs

Parabolic Drugs has entered the dosage space with an aim to make Rs 150 crore by way of sales within 3-5 years, said director Vineet Gupta.

Parabolic Drugs set to launch 17 products in 3 yrs

Vineet Gupta, director of Parabolic Drugs spoke to CNBC-TV18 about the latest with is company and the way ahead.

Parabolic Drugs in talks with cos for bulk supply deals

There are reports stating that Parabolic Drugs is in talks with Japanese firms for bulk supply deals. In an interview to CNBC-TV18, Vineet Gupta, director of Parabolic Drugs confirmed the same.

Parabolic Drug in talks for bulk supply deals; stock up 11%

Parabolic Drugs is in talks with Japanese firms for bulk supply deals. The company is expected to start supplying to Japan by next fiscal-end, reports CNBC-TV18, quoting DowJones. It touched an intraday high of Rs 31 and an intraday low of Rs 27.50. At 10:22 hrs the share was quoting at Rs 30.60, up Rs 3.05, or 11.07%.

Parabolic Drugs board meets on August 13; stock up 5%

Parabolic Drugs has board meeting on August 13 to consider preference issue of convertible warrants, reports CNBC-TV18. It touched an intraday high of Rs 34.20 and an intraday low of Rs 32.55. At 13:20 hrs the share was quoting at Rs 34.00, up Rs 1.65, or 5.10%.

With 3 new expansions, FY12 to see 25% growth: Parabolic

Parabolic Drugs recently announced its results for the fourth quarter and for the financial year that ended March 31, 2011. Vineet Gupta, director of the company, says he is hopeful that new expansions “will help contribute to further margin expansion.”

Parabolic gets certificate of suitability for Cefixime

Parabolic Drugs said on Monday it has received a certificate of suitability (COS) for its key molecule Cefixime in the European Union.

Parabolic gets Europe certificate; stock gains 3%

Parabolic Drugs has got Europe certificate of suitability for Cefixime, reports CNBC-TV18. It touched an intraday high of Rs 49.50 and an intraday low of Rs 46.10. At 10:50 hrs the share was quoting at Rs 48.10, up Rs 1.40, or 3%.

Parabolic eyes Rs 20cr sales via new alliance next year

In an interview with CNBC-TV18’s Latha Venkatesh and Reema Tendulkar, Vineet Gupta, Director of Parabolic Drugs, spoke on their pact with a local company on manufacturing nutraceutical bulk drugs.

Parabolic Drugs plans 5 molecule launches by end-Apr

In April 2008, IDFC Private Equity, one of the largest private equity firms in the country, floated a separate renewable energy company, Green Infra Limited, with a vision to become the largest and the most valuable independent power producer in the country.

Parabolic Drugs eyes Rs 900cr sales next year

In an interview CNBC-TV18, Vineet Gupta, Director, Parabolic Drugs, speaks about the results and gives his outlook going forward.

Parabolic Drugs to announce CRAMS deals with European cos

Parabolic Drugs may announce CRAMS deals with European companies soon, reports CNBC-TV18. It touched an intraday high of Rs 62.30 and an intraday low of Rs 57.20. At 15:28 hrs the share was quoting at Rs 59.90, down Rs 0.60, or 0.99% on the NSE.